Pulmonary Antihypertensive Agents, cGMP pathway

Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling

Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP By facilitating smooth muscle relaxatio...

They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP

They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP

By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)

By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)

By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)